The Company’s best-in-class drug development strategy focuses on anti-cancer therapy. Our lead compound SDX-7320 is in pre-clinical development for solid tumors and shows surprising activity at low doses. It combines two functional parts: a novel MetAP2 inhibitor coupled to a bio-compatible, stable polymer backbone, clinically proven to improve safety, bio-distribution, tumor targeting, and pharmacokinetics of the attached active drug. This rational approach reduces development risk and represents the next generation of targeted cancer therapy.
Non-degradable polymer backbones are preferred over degradable polymers because they do not release drug prematurely in general circulation, thus reducing toxicities. Pre-clinical testing of SDX-7320 in multiple tumor cell lines has shown surprising activity results, which we believe will translate into human clinical benefit.
Mechanism of delivery: Polymer acts as "warhead"
Rational Drug Development
The concept is simple: small molecules are easier to manufacture and characterize than large proteins or monoclonal antibodies, but are indiscriminate in their targeting. That makes them prone to cause a host of unwanted side effects. By conjugating (or attaching) the active small molecule using our proprietary approach to a larger bio-compatible - and importantly - non bio-degradable polymer, the active drug is rendered inert while in general circulation, and so the side effects are minimized.
One Broadway, 14th Floor, Cambridge MA 02142 Tel: 617.401.3110
